Clinical Evidence Generation During a Pandemic
Authors:
- Donna R. PharmD RiveraDRDonna R. PharmD Rivera
- Paul G. KluetzPKPaul G. Kluetz
- Kald AbdallahKAKald Abdallah
- Sundeep AgrawalSASundeep Agrawal
- Derek C. AngusDADerek C. Angus
- Robert M. CaliffRCRobert M. Califf
- Elizabeth Garrett-MayerEGElizabeth Garrett-Mayer
- Randall HyerRHRandall Hyer
- Douglas R. LowyDLDouglas R. Lowy
- Samir N. KhleifSKSamir N. Khleif
- 28 March 2022
- journal article
- review article
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 28 (2) , 151-156
Abstract
Because of significant adaptations forced by the COVID-19 pandemic, resultant changes within health care delivery and clinical research introduced the potential for evaluation of novel evidence generation approaches in oncology. On July 26 and 27, 2021, the National Academies of Science, Engineering, and Medicine, National Cancer Policy Forum hosted a virtual workshop entitled “Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic: A Workshop on Lessons Learned.” This workshop examined changes in cancer care and cancer research that occurred in response to the COVID-19 pandemic and considered lessons learned from that experience. The goal was to identify what changes could improve the delivery of high-quality cancer care and the conduct of cancer clinical trials in the postpandemic era, with an emphasis on health equity. How can we sustain the valuable lessons learned that might accelerate progress and enhance clinical evidence generation for patients and clinicians? In this overview, we discuss ways in which the COVID-19 experience has catalyzed research efficiencies as well as fostered a broader array of trial design and research methods that may facilitate improved cancer drug development during the pandemic and beyond.Keywords
This publication has 27 references indexed in Scilit:
- Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19JAMA, 2020
- Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort StudyCancer Discovery, 2020
- The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and DesignAnnals of the American Thoracic Society, 2020
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyThe Lancet, 2020
- The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with CancerCancer Cell, 2020
- Considerations for pharmacoepidemiological analyses in the SARS‐CoV‐2 pandemicPharmacoepidemiology and Drug Safety, 2020
- Enhancing clinical evidence by proactively building quality into clinical trialsClinical Trials, 2016
- Registry-based randomized clinical trials—a new clinical trial paradigmNature Reviews Cardiology, 2015
- Guidelines for good pharmacoepidemiology practices (GPP)Pharmacoepidemiology and Drug Safety, 2008
- Why do we need some large, simple randomized trials?Statistics in Medicine, 1984